Genetron was founded in 2013 with the mission to use genomic insights to transform cancer care.
In less than 8 years, our team has made remarkable progress—with technological breakthroughs & major milestones that have helped impact the cancer early detection paradigm. See our journey below.
Research Breakthrough: "Exome sequencing identifies somatic gain-of-function PPM1D mutations in brainstem gliomas" (Nature Genetics)
Research Breakthrough: "Genetic landscape of esophageal squamous cell carcinoma" (Nature Genetics)
Research Breakthrough: "Recurrent gain-of-function USP8 mutations in Cushing's disease" (Cell Research)
Research Breakthrough: "The genome-wide mutational landscape of pituitary adenomas" (Cell Research)
Approval of IDH1 Gene Mutation Test
Approval of TERT Gene Mutation Test
Approval of biochip reader GENETRON 3D
Research Breakthrough: "The genomic landscape of TERT promoter wildtype-IDH wildtype glioblast" (Nature Communications)
Research Breakthrough: "Identification of recurrent USP48 and BRAF mutations in Cushing’s disease" (Nature Communications)
Research Breakthrough: "Biological Role and Therapeutic Potential of IDH Mutations in Cancer" (Cancer Cell)
Research Breakthrough: "Molecular profiling of tumors of the brainstem by sequencing of CSF-derived circulating tumor DNA" (Acta Neuropathologica)
Prospective cohort study for early stage liver cancer: "SCREENING of early-stage hepatocellular carcinoma in asymptomatic HBsAg-seropositive individuals by liquid biopsy" (PNAS)
Approval of gene sequencer GENETRON S5
Approval of automatic sample loading system GENETRON Chef
Approval of gene sequencer GENETRON S2000
Approval of 8 Gene Mutation Test
Research Breakthrough: (Nature Communications)
Contributed to the establishment of China's first-ever 'NGS Clinical Application Standards'
Joined the "Liver Cancer Early SCREENING Comprehensive Prevention" public health initiative